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Review article 
Ανασκόπηση
ABSTRACT: Injection site sarcomas (ISS) are tumours of tissues of mesenchymal origin that occur at an injection 
site. These tumours have been mainly described in cats as Feline injection-site sarcoma (FISS), but suspected cases 
have also been described in other species such as dogs. In other species than the domestic cat, these tumours are how-
ever much rarer. As a result, the body of literature is limited. This review aims to summarize the knowledge regarding 
ISS in species other than the domestic cat. In general, it seems that ISS can occur in a wide range of animals and that 
similar treatment strategies are employed as in cats. Like in cats, it seems that the benefit of the reasons for injection 
(such as vaccination and microchip implantation) could outweigh the risk of ISS development in other species. 
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Injection site sarcomas (ISS) are tumours of tissues of mesenchymal origin that occur at an injection 
site (Zabielska-Koczywąs, Wojtalewicz, et al., 2017).
These tumours have been mainly described in cats as 
Feline injection-site sarcomas (FISS), where they oc-
cur in about 1-10 of every 10,000 vaccinations (Zabiel-
ska-Koczywąs, Wojtalewicz, et al., 2017). A chronic 
inflammatory response at the injection site has been 
described as the hypothesis for the neoplastic dis-
ease (Woodward, 2011; Hartmann, Day, et al., 2015).
Several studies have been conducted to investigate 
FISS. This includes studies regarding, among others, 
treatment strategies (Cohen, Wright, et al., 2001), risk 
factors (Kass, Spangler, et al., 2003) and immunohis-
tochemistry (Carneiro, de Queiroz, et al., 2018). The 
current state of knowledge was summarized in several 
reviews (Saba, 2017; Zabielska-Koczywąs, Wojtale-
wicz, et al., 2017).
In addition to cats, suspected cases of these tu-
mours have also been described in other feline spe-
cies such as a lion (Kinne and Tarello, 2007) and in 
non-feline species such as dogs (Jacobs, Poehlmann, 
et al., 2017).This type of cancer is however very rare 
in other species than the domestic cat. As a result, the 
available literature about the condition in these spe-
cies is sparse. 
Due to the role of dogs as companion animals and 
the frequency of injections (e.g. for vaccinations and 
microchip implantations) performed, it is useful to 
also investigate ISS in these animals. Furthermore, in-
vestigating ISS in more exotic animals could provide 
more information on the condition in general and as-
sess what factors (e.g. risk factors and treatment out-
comes) are species-specific and which factors can be 
generalized.
The current review aims to briefly summarise the 
limited evidence about this condition in other species 
than the domestic cat. 
SEARCH STRATEGY
To identify relevant literature regarding injection 
site sarcoma the Pubmed, Pubmed Central, Google 
Scholar and Web of Science databases were searched. 
Database-specific variants of the “injection site sarco-
ma”, “injection site tumour”,“injection site cancer”,“-
vaccine-associated sarcoma”, “vaccine-associated 
tumour” and “vaccine-associated cancer”, “foreign 
body sarcoma”, “foreign body tumour”, “foreign 
body cancer”, “foreign body tumorigenesis”, “micro-
chip sarcoma”, “microchip tumour” and “microchip 
cancer” search strings were used. Subsequently, the 
references of the selected publications were searched 
for further relevant literature.
IDENTIFIED LITERATURE
The relevant literature identified consisted mainly 
of case reports and case series describing a limited 
number of animals. The species for which literature 
was identified were: dogs (Jacobs, Poehlmann, et 
al., 2017), ferrets (Munday, Stedman, et al., 2003), 
a lion (Kinne and Tarello, 2007), a rabbit (Petteri-
no, Modesto, et al., 2009) and a horse (Kannegieter, 
Schaaf, et al., 2010). 
The dog is the most frequent species apart from 
cats for which suspected cases of ISS have been de-
scribed. In 2003, Vascellari and colleagues described 
15 cases of fibrosarcoma excised from where injec-
tions were thought to have been performed (Vascel-
lari, Melchiotti, et al., 2003).In a later publication in 
2006, Vascellari and colleagues described a case re-
port of a dog with a fibrosarcoma in the back of the 
neck. The dog received several previous injections 
at this site, both for vaccinations and the placement 
of a microchip (Vascellari, Melchiotti, et al., 2006). 
In 2016, a case of extraskeletal osteosarcoma in the 
interscapular region in a dog was described (Selmic, 
Griffin, et al., 2016). The animal had received several 
injections at this site before. Jacobs et al. described a 
case of possible canine injection site sarcoma in 2017 
(Jacobs, Poehlmann, et al., 2017).The dog developed 
tumours in the dorsocervical area after receiving in-
jections at this site 3 weeks before.
In 2003, a retrospective case series of fibrosarco-
mas in ferrets was published (Munday, Stedman, et 
al., 2003). Seven of these fibrosarcomas occurred at a 
site regularly used for vaccinations. 
In 2009, a case of interscapular fibrosarcoma in 
a rabbit was published (Petterino, Modesto, et al., 
2009). The tumour developed at a site where several 
injections were performed. The authors stated that the 
histology of the tumour resembled that of a FISS.
A single case report of ISS in a horse was pub-
lished in 2010 (Kannegieter, Schaaf, et al., 2010). 
This animal developed a fibrosarcoma 2 weeks after 
vaccination for equine influenza. 
Finally, FISS has also been described in other fe-
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 10/12/2021 10:00:37 |
J HELLENIC VET MED SOC 2021, 72(3)
ΠΕΚΕ 2021, 72(3)
3003J. STANS
line species than the domestic cat. In 2007, a case re-
port of potential injection site sarcoma was described 
in a lion (Kinne and Tarello, 2007). The animal devel-
oped fibrosarcoma around 2 months after being vac-
cinated for feline leukaemia virus, feline rhinovirus 
and rabies. These authors also refer to a conference 
proceeding reporting a case of FISS in a tiger in 1998 
(Kinne and Tarello, 2007). This publication was un-
fortunately not able to be sourced.
It is clear that the body of literature regarding 
ISS apart from the domestic cat is very limited as 
compared to literature about FISS. This supports 
the hypothesis that the condition is rare outside of 
the domestic cat. Other factors such as less reports 
and injection frequency in other species could also 
contribute to the smaller number of publications. It 
should also be noted that in most cases no assessment 
was performed to establish a causal relationship be-
tween an injection and the development of neoplastic 
disease. Additionally, almost all literature consists of 
case reports and case series describing a limited num-
ber of animals. Afinal observation is that a substantial 
amount of the identified literature regarding ISS apart 
from the domestic cat has been published more than 
10 years ago.New research could provide important 
insights regarding potential changes in the incidence 
or characteristics of this condition.
CASE CHARACTERISTICS AND RISK 
FACTORS
The average age of cats affected by FISS was 
between 8 and 9 years in several studies (Hendrick, 
Shofer, et al., 1994; Doddy, Glickman, et al., 1996; 
Vascellari, Melchiotti, et al., 2003).The majority of 
FISS cases have been reportedto occur between 4 
months and 3 years after injection (Hartmann, Day, et 
al., 2015). Fibrosarcomas are the most frequent kind 
of FISS(Doddy, Glickman, et al., 1996). In cats, it 
has been found that the risk of developing ISS does 
not vary between vaccine brands or manufacturers 
(Kass, Spangler, et al., 2003). The identified literature 
for ISS except that concerning the domestic cat was 
screened for several factors, including vaccine brand, 
age and injection site.
The dogs affected by potential ISS in the case se-
ries were on average 6.2 years old, but the age ranged 
from 7 months to 11 years (Vascellari, Melchiotti, et 
al., 2003). The animals in the case report were respec-
tively 9, 6 and 11 years old (Vascellari, Melchiotti, et 
al., 2006; Selmic, Griffin, et al., 2016; Jacobs, Poehl-
mann, et al., 2017). In almost all of these cases, the 
presumed ISS was a fibrosarcoma, except for the 2016 
case report (Selmic, Griffin, et al., 2016), where an 
osteosarcoma was diagnosed. Several breeds of dogs 
have been described that developed presumed ISS. In 
the case series (Vascellari, Melchiotti, et al., 2003), 
mixed breeds (6/15), Collie (1/15), German Shepherd 
(1/15), Schnauzer (1/15), Chow-Chow (1/15), Gold-
en Retriever (1/15), American Pit Bull (1/15) Siberian 
Husky (1/15), Drahthaar (1/15) and Irish Setter (1/15) 
were reported. The case reports mention a French 
Bulldog (Vascellari, Melchiotti, et al., 2006), a Lab-
rador (Selmic, Griffin, et al., 2016) and a Labrador 
Retriever(Jacobs, Poehlmann, et al., 2017). Based on 
these limited data, it is difficult to assess whether cer-
tain breeds have a predisposition to develop ISS. It is 
possible that this distribution is a normal variation or 
simply a reflection of the breeds that are usually kept. 
It is however apparent that the condition can develop 
in a wide variety of breeds. FISS has been estimat-
ed to occur in 1 - 10 of every 10,000 vaccinations in 
cats (Zabielska-Koczywąs, Wojtalewicz, et al., 2017).
Because of the scarcity of the literature and the lack 
of epidemiological studies, it is difficult to assess the 
incidence of ISS in dogs. However, due to the wide-
spread vaccination in dogs and the relative rarity of 
case reports in dogs as compared to cats, it can be 
hypothesized that the incidence in dogs is less than 
the incidence mentioned for FISS.
The age of the ferrets with sarcomas at an injec-
tion site in the study of Munday (Munday, Stedman, 
et al., 2003) ranged from 1 to 9 years. This study fo-
cused solely on fibrosarcomas. However, no literature 
regarding other sarcoma types at injection sites was 
identified for this species.
The dwarf rabbit in the 2009 case report was 1 
year old when it received a vaccination (Petterino, 
Modesto, et al., 2009).  However, when it developed a 
fibrosarcoma, it was already 8 years old.
The horse described in the case report of Kanneg-
ieter was 12 years old and a Quarterhorse x Arabian 
(Kannegieter, Schaaf, et al., 2010). It developed a fi-
brosarcoma.
The lion developing a fibrosarcoma was only 8 
months old (Kinne and Tarello, 2007).
TREATMENT AND OUTCOME
FISS in the domestic cat is usually treated by 
surgical removal of the tumour, with wide margins. 
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 10/12/2021 10:00:37 |
J HELLENIC VET MED SOC 2021, 72(3)
ΠΕΚΕ 2021, 72(3)
3004 J. STANS
If indicated, adjuvant treatment strategies such as 
radio- and chemotherapy can also be performed(Z-
abielska-Koczywąs, Wojtalewicz, et al., 2017). De-
spite treatment, frequent local recurrence has been 
described (Hartmann, Day, et al., 2015). Metasta-
sis has also been described in several cases (Saba, 
2017). 
The samples of the 15 fibrosarcomas described by 
the group of Vascarelli (Vascellari, Melchiotti, et al., 
2003) were obtained from dogs that underwent sur-
gical removal of their tumour. It is not clear whether 
these animals received any additional therapy such as 
chemotherapy or radiation. The survival outcomes or 
the presence of metastatic disease were not reported. 
In the case report published in 2006, the tumour was 
surgically removed taking into account margins of 2 
cm (Vascellari, Melchiotti, et al., 2006).The authors 
state that the dog was doing well and that there has 
been no sign of recurrence. The canine osteosarco-
ma described in 2016(Selmic, Griffin, et al., 2016)
was initially surgically removed with wide margins. 
No metastasis was revealed at this time. A subsequent 
surgical site infection was treated with amikacin, 
followed by cefpodoxime proxetil and finally chlor-
amphenicol after subsequent cultures. A carboplatin 
treatment was initiated to control microscopic metas-
tases. During chemotherapy treatment, no metastases 
were identified. However, 1 month after the final cy-
cle of chemotherapy, a suspected metastasis was iden-
tified in the right lung. Afterwards, a toceranib phos-
phate and cyclophosphamide treatment was initiated. 
Eighteen months after diagnosis, the animal present-
ed with bone metastatic disease. Toceranib phosphate 
and cyclophosphamide treatment were discontinued. 
Afterwards, the animal was treated with fractioned 
radiotherapy. The animal was euthanised 20.5 months 
after diagnosis. The dog in the more recent case re-
port (Jacobs, Poehlmann, et al., 2017) had a surgical 
removal of the tumour with margins of 3 cm. After 10 
weeks, a recurrence of the tumour was noted. Lung 
metastasis was not present. A new surgical excision 
with 3 cm margins was carried out. Additionally, a 
three-days a week schedule of toceranib was started. 
No metastatic disease was noticed during this therapy. 
Fifty weeks after the first surgical removal, the same 
procedure had to be carried out for a third time due 
to a new recurrence, together with a continuation of 
the tyrosine kinase inhibitor therapy. The authors re-
ported that the animal was still in remission almost 2 
years after the diagnosis.
A multi-institutional retrospective study combin-
ing different treatment strategies in dogs could prove 
to be clinically useful if a large number of institutions 
participate and the inclusion criteria are not too strict, 
for example by allowing all FISS tumour types and 
treatment types.This way, a large number of cases can 
be assessed especially concerning relations between 
various treatment management strategies, quality of 
life after treatment and possible complications. A dis-
advantage of this kind of approach is that it is difficult 
to connect particular treatment strategies with surviv-
al outcome
The initial treatments for the ferrets in the case 
series of Munday and colleagues (Munday, Stedman, 
et al., 2003) were not detailed. It can however be as-
sumed that the tumours were partially or complete-
ly surgically removed, since samples were available. 
Information about other therapies were not available. 
The authors report follow-up data for 3 of the animals 
that had fibrosarcoma at an injection site. One animal 
had a tumour recurrence 3 months after surgery and 
was euthanised. Two other animals did not have re-
currence 8 and 12 months after surgery.
The fibrosarcoma in the rabbit in the case report 
of Petterino and colleagues (Petterino, Modesto, et 
al., 2009) was surgically removed with wide margins. 
After 2 months, the tumour recurred at the same site. 
The animal was subsequently euthanised.
The fibrosarcoma in the horse of the case report of 
Kinnegieter and colleagues (Kannegieter, Schaaf, et 
al., 2010) was surgically removed without radiother-
apy or chemotherapy. No metastasis to lymph nodes 
or distant organs was identified. After 4 months, there 
was no recurrence of the tumour found.
In the case report by Kinneand Tarello (Kinne 
and Tarello, 2007), the lion was treated by surgical 
removal of the tumour. Despite radiotherapy being 
indicated, it was not performed due to practical con-
siderations. The animal was later euthanised due to 
the poor prognosis. The time between diagnosis or 
treatment and death was not reported.
Due to the rarity of this disease in species out-
side of the domestic cat, it is unlikely that a clinical 
trial assessing treatment strategies will be feasible. 
However, there is currently consensus that FISS 
should be treated with surgical removal. Based on the 
literature mentioned above, it seems that this treat-
ment strategy is also the treatment of choice for ISS 
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in other species. 
CONCLUSION
The literature regarding ISS outside of domesticat-
ed cats is very sparse. Despite this limited body of 
evidence, ISS has been described in dogs, ferrets, a 
rabbit, a horse and a lion. However, in most of these 
cases no assessment regarding a causal link between 
injections and the neoplasm was made. In general, 
treatment strategies of FISS and ISS in other species 
are similar. Based on the current literature, it seems 
that the benefits of the reasons for injection could 
outweigh the risk of developing ISS in all species. 
It should be noted, however, that this conclusion is 
based on a very limited amount of evidence. Further 
research should be performed to better understand the 
epidemiology, causes and risk factors of ISS in other 
species than the domestic cat and to discover optimal 
treatment strategies.
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